Physician profile
Meagan Steele
NPI 1033860572
$1,338.04
in general payments reported to CMS, 2019-2025
21 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $390 · 2023: $427 · 2024: $341 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $194.74 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $171.06 | 2022-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $165.52 | 2022-2024 | |
| Lilly USA, LLC | $123.83 | 2022-2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $85.40 | 2023 | Quviviq |
| Neurocrine Biosciences, INC. | $82.68 | 2025 | |
| Emd Serono, INC. | $80.31 | 2024 | |
| Sanofi Pasteur INC. | $75.68 | 2023 | |
| Biogen, INC. | $70.07 | 2024 | |
| Glaxosmithkline, LLC. | $53.88 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Medtronic, INC. | $48.58 | 2022-2023 | Closurefast |
| Corcept Therapeutics | $27.26 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.84 | 2022 | |
| Nestle Healthcare Nutrition INC. | $20.21 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.66 | 2023 | Farxiga |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impel Pharmaceuticals INC. | $17.11 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.91 | 2022 | |
| Exact Sciences Corporation | $16.81 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $16.38 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.36 | 2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meagan Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.